CYCLACEL PHARMACEUTICALS INC (CYCC) Stock Income Statement
USA - NASDAQ:CYCC - US23254L8019 - Common Stock
6.365 USD
-0.4 (-5.98%)
6.4 USD
+0.04 (+0.55%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.00K | 43.00K | 420.00K | 0.00 | 0.00 | |||
| Operating Expenses | 10.37M | 12.05M | 25.87M | 27.66M | 22.94M | |||
| Research and Development | 2.72M | 6.66M | 19.16M | 20.27M | 15.48M | |||
| Selling, General, and Administrative Expenses | 7.65M | 5.39M | 6.72M | 7.38M | 7.46M | |||
| Operating Income | -10.36M | -12.00M | -25.45M | -27.66M | -22.94M | |||
| Interest Income/Expense | -23.00K | -42.00K | -148.00K | 440.00K | 60.00K | |||
| Other Income/Expense | N/A | 52.00K | 50.00K | 1.30M | 140.00K | |||
| Income Before Taxes | -5.42M | -11.99M | -25.55M | -25.92M | -22.73M | |||
| Income Tax | 986.00K | -782.00K | -3.00M | -4.72M | -3.85M | |||
| Net Income | -6.43M | -11.21M | -22.76M | -21.40M | -19.09M | |||
| EBITDA | N/A | -12.00M | -25.42M | -27.63M | -22.90M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -122.02 | -502.55 | -6.41K | -6.84K | -7.70K | |||
| Non GAAP EPS | N/A | N/A | -435.68 | -456.00 | -513.60 | |||
| Statistics | ||||||||
| Profit Margin | -64280.00% | -26074.42% | -5418.10% | N/A | N/A | |||
| Operating Profit Margin | -103580.00% | -27916.28% | -6060.24% | N/A | N/A | |||
All data in USD